First Patient Dosed at Ribocure Clinic
With the ambition to become a world-leading clinical oligonucleotide research company, Ribocure Pharmaceuticals AB has established Ribocure Clinic, to focus on high-quality Proof of Principle Ph2 studies. The clinic has now dosed its first patient in a Phase 2 study using the world’s first and most advanced hemostasis sparing anti-thrombotic siRNA drug, RBD4059. Ribocure Clinic, […]
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) have entered a strategic partnership with Pheiron to leverage its cutting-edge AI platform, PheironGPS, in Ribo’s discovery and development of RNA-based therapeutics. This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating advanced human evidence generated through Pheiron’s AI technology. PheironGPS […]
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
On September 10, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a first-in-human (FIH) Phase I clinical trial in Sweden with the siRNA drug, RBD7007 targeting C5. This is a first-in-human (FIH) phase 1 trial to assess the safety, tolerability, and […]
Ribo presented the first clinical data from our completed Ph1 study of the world’s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.
We thank the European Society of Cardiology #ESC Congress, session chairs, and all participants in the session for the opportunity and attention. We look forward to continuing the further clinical development of RBD4059 based on our Phase 1 results. “We are excited to have progressed world’s first and most advanced FXI siRNA program, now into […]
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the world’s first siRNA drug targeting Factor XI: RBD4059
On May 27, 2024, Ribocure Pharmaceuticals AB and Suzhou Ribo Life Science Ltd (Ribo) received authorization from the Swedish Medicinal Product Agency (MPA), to initiate a Phase II clinical trial in Sweden with the world’s first and most advanced anti-thrombotic siRNA drug, RBD4059 targeting FXI. The trial will evaluate safety, pharmacokinetics and pharmacodynamics of its […]
Join us in celebrating Clinical Trials Day!
Today we highlight the Clinical Trials Day and the importance of clinical research at Ribocure Pharmaceuticals and Ribocure Clinic. Ribocure Clinic is our specialized clinical trial unit with highly trained medical research staff for Phase 2 trials in cardiovascular, pulmonary, renal and liver disease, where advanced imaging and functional assessments are applied. Read more about […]
Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe
Ribocure Pharmaceuticals/Suzhou Ribo Life Science Co. Ltd. (“Ribo”) announce Notice of Allowance issued respectively by US Patent Office and European Patent Office for patent applications covering the anti-hepatitis B siRNA drug RBD1016. With the approved patents in US and Europe, and with the previous authorizations in six major countries/regions, including China and Japan, Ribo’s strategy […]
Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)
On April 10, 2024, Ribo and Ribocure announce the completion of enrolment and dosing of the Ph1 clinical trial with world’s first and most advanced anti-thrombotic siRNA drug, RBD4059, targeting coagulation factor XI (FXI). The Phase I clinical trial is a randomized, single-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and potency of RBD4059 […]
Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA
Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection. Ribocure Pharmaceuticals AB, the international research center of Suzhou Ribo Life Science Ltd, […]
Ribocure supports WORLD KIDNEY DAY on March 14th
Ribocure Pharmaceuticals AB is a clinical stage biotech company developing oligonucleotide-based therapeutics (siRNA). Across the globe, chronic kidney disease (CKD) affects around 700 million people, with 3.1 million deaths attributable to kidney dysfunction, making it the seventh leading cause of mortality worldwide. Low- and middle-income countries bear a disproportionate burden of CKD and kidney failure. Multiple […]
